Treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer.

Palbolieva 125mg Capsule works by blocking the protein called cyclin-dependent kinases 4 and 6, which are vital for the division and growth of cells. By blocking these proteins, this medication slows the growth and prevents the cancer cells from spreading.

Inform your doctor about any medications you are taking or have taken before the treatment. Concurrent use of Palbolieva 125mg Capsule with CYP3A4 inhibitors such as fentanyl has reported increased fentanyl toxicity.

• Keep Palbolieva 125mg Capsule out of sight and reach of children.

• Store at 20°C to 25°C.

Take Palbolieva 125mg Capsule exactly as prescribed by your doctor. Take this medication once a day at the same time with food. Swallow this capsule as a whole with a glass of water. Avoid crushing, breaking, or chewing the capsule.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Palbolieva 125mg side effects are

Serious

• Blood disorder (fever, chills, shortness of breath, weakness, bleeding, or bruising)

• Lung inflammation (chest pain, dry cough, or difficulty breathing)

Common

• Tiredness

• Hair loss

• Dry skin, rash

• Infections

• Low blood cell counts

• Decreased of appetite

• Nausea, vomiting

• Diarrhea

• Swelling of lips and mouth

• Changes in taste

• Nose bleed

• Dry eye, blurred vision, increased tearing

• Avoid consuming grapefruit, grapefruit juice, and products containing St. John’s wort during Palbolieva 125mg Capsule treatment.

• Use effective birth control while on treatment and for at least three weeks after the final dose if you are female, and for at least fourteen weeks after the final dose if you are male.

• This medicine may reduce fertility, so speak with your doctor if you have any fertility-related concerns.

• Your doctor may advise regular blood tests to monitor whether the treatment is affecting your blood cell levels.

1. Pfizer Limited, Electronic medicines compendium (emc), [Revised on June 2021] [ Accessed on 26 Nov 2022], https://www.medicines.org.uk/emc/files/pil.4449.pdf
2. Pfizer Labs, US Food and Drug Administration, [Revised on March 2017] [ Accessed on 26 Nov 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf
3. Neha S Mangini et al; Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer; The Annals of Pharmacotherapy; Published on Nov 2015; Accessed on 26/11/2022; https://pubmed.ncbi.nlm.nih.gov/26324355/
4. Palbace; Pfizer; Revised on Oct 2021; Accessed on 26/11/2022; https://labeling.pfizer.com/ShowLabeling.aspx?id=14029